TGFB1 and metabolic dysfunction-associated steatotic liver disease: In a study conducted by Qin et al. [37] the capacity of isoquercetin to ameliorate hepatic lipid accumulation in an HFD-induced MASLD rat model was attributed to its ability to activate the AMPK pathway and suppress the TGF-β pathway.